Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Calcineurin is a Ca 2+ -calmodulin-activated serine/threonine-specific protein phosphatase that governs multiple aspects of fungal physiology, including cation homeostasis, morphogenesis, antifungal drug susceptibility, and virulence. Growth of Candida albicans planktonic cells is sensitive to the calcineurin inhibitors FK506 and cyclosporine A (CsA) in combination with the azole antifungal fluconazole. This drug synergism is attributable to two effects: first, calcineurin inhibitors render fluconazole fungicidal rather than simply fungistatic, and second, membrane perturbation by azole inhibition of ergosterol biosynthesis increases intracellular calcineurin inhibitor concentrations. C. albicans cells in biofilms are up to 1,000-fold more resistant to fluconazole than planktonic cells. In both in vitro experiments and in an in vivo rat catheter model, C. albicans cells in biofilms were resistant to individually delivered fluconazole or calcineurin inhibitors but exquisitely sensitive to the combination of FK506-fluconazole or CsA-fluconazole. C. albicans strains lacking FKBP12 or expressing a dominant FK506-resistant calcineurin mutant subunit (Cnb1-1) formed biofilms that were resistant to FK506-fluconazole but susceptible to CsA-fluconazole, demonstrating that drug synergism is mediated via direct calcineurin inhibition. These findings reveal that calcineurin contributes to fluconazole resistance of biofilms and provide evidence that synergistic drug combinations may prove efficacious as novel therapeutic interventions to treat or prevent biofilms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 and calcineurin are well known to affect fungal drug responses, including the cidality of azoles 26,32,42,43,70,71 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous findings have indicated little or no effect for treatment of mature biofilms when FLU is used in combination with other antifungals, including AmB and CAS [10], whereas synergistic effects (similar to the enhanced effect reported in this study) have been observed when FLU is combined with calcium channel inhibitors [11] and doxycycline [12], among others.”
From In vitro analysis of flufenamic acid activity against Candida albicans biofilms (2014) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511 · cited 2×
“albicans biofilm resistance to fluconazole is considered multifactorial, encompassing contributions of cell density, impermeability of drugs through the extracellular matrix, activation of multidrug efflux pumps, increases in cellular -1,3 glucan levels, and decreases in sterol levels (5, 20, 22, 26).”
BackgroundNosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“albicans can enter the bloodstream to cause serious systemic invasive disease (6, 38).”
BackgroundPutative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407 · cited 3×
“A recent report also demonstrated that cell wall -1,3 glucan levels contribute to biofilm resistance to fluconazole (22).”
BackgroundMethodSelf-citationBaillie, G. S. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.397 · Cited by 389
Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Self-citationSanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350
Calcineurin is essential for survival during membrane stress in Candida albicans
Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H., & Heitman, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.546 · Cited by 342 · cited 15×
“albicans, calcineurin is required for survival in serum, virulence, and resistance to azole antifungals, in part via its downstream target, Crz1 (7, 9, 11, 15).”
BackgroundInfluentialSelf-citationBiochemical Targets for Antifungal Azole Derivatives: Hypothesis on the Mode of Action
Vanden Bossche, H. (1985) · Current Topics in Medical Mycology · doi:10.1007/978-1-4613-9547-8_12 · Cited by 321
Cited by
Items 201–228 of 228
Evolutionary diversity of the control of the azole response by Tra1 across yeast species
Marsiglio-Librais, G. N., Jiang, Y., Razzaq, I., Brandl, C. J., Shapiro, R. S., & Lajoie, P. (2023) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkad250 · Cited by 1
The Role of Biofilm Matrix in Mediating Antifungal Resistance
Nett, J. E., & Andes, D. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_20-1 · Cited by 2
Self-citationFungi as Eukaryotes: Understanding the Antifungal Effects of Immunosuppressive Drugs
Schaenman, J. M. D., Khuu, T., & Kubak, B. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0169-3 · Cited by 1
ANTIFUNGAL AGENTS IN TERMS OF ACQUIRED RESISTANCE IN CANDIDA SPECIES
Iungin, O. S. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-2-144-83-86 · Cited by 3
In the Crossroad Between Drug Resistance and Virulence in Fungal Pathogens
Cavalheiro, M., & Teixeira, M. C. (2018) · Springer eBooks · doi:10.1007/978-3-030-00683-9_7 · Cited by 1
Investigating How Ploidy and Stress-induced Ploidy Change Affects Fitness in Candida albicans
Hougard, J. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
The role of adjuvant agents in treating fungal diseases
Grim, S. A., & Clark, N. M. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0016-8
Overcoming the antifungal drug resistance of biofilms on dental acrylic
Newsham-West, K. (2013) · Otago University Research Archive (University of Otago) · Cited by 1
Lopes, M. D. C. G. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
In Vitro Screening of Antifungal Compounds Able to Counteract Biofilm Development
Girardot, M., & Imbert, C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0467-9_13
Shekhar‐Guturja, T. (2016) · TSpace (University of Toronto)
The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance
Singh, S. (2012) · TSpace (University of Toronto)
Hill, J. A. (2014) · TSpace (University of Toronto)
Jafri, H., Samreen, S., Qais, F. A., Abulreesh, H. H., & Ahmad, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88480-8.00003-0
Analysis of Candida Antifungal Resistance Using Animal Infection Models
Andes, D. R., & Nett, J. E. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3155-3_16 · Cited by 1
Self-citationEffectiveness of drug repurposing approach against Candida isolates
Ansari, A., Saini, M. K., Kumar, D., Rai, N., & Kumar, N. (2024) · Environment Conservation Journal · doi:10.36953/ecj.30540224
Novel Therapeutic Approaches to Control Fungal Biofilms
Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11
Composition and Role of the Extracellular Matrix in Fungal Biofilm Drug Resistance
Kim, M.-J., Żarnowski, R., & Andes, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_8 · Cited by 1
Self-citationRodríguez, A. V., Rodrigues, C. F., Ramage, G., & Lopez-Ribot, J. L. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_12 · Cited by 1
Singh, D., Brink, J., Hiebner, D. W., & Casey, E. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5779304
Cen, Y., Zhang, L.-L., Zhang, Z., Zhang, Y.-J., Lu, T.-X., Zhou, W.-Y., Xiang, C., Xue, Y., & Zheng, Y. (2025) · Biochemical Journal · doi:10.1042/bcj20253193
Ayala, M., Jakamartana, A., Costa, R. M. D. S., Bednarek, J. M., Moreau, C. T., Cheung, C. K., & Brown, J. C. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.31.697249
A Calcineurin Inhibitor as an Enhancer of Candida Susceptibility to Anidulafungin
Rovira, I., Montemayor, E., Gil-Alonso, S., Miranda-Cadena, K., Sánchez, F., Quindós, G., Eraso, E., & Jauregizar, N. (2026) · ACS Omega · doi:10.1021/acsomega.5c10111
Matsumoto, Y., Shimizu, Y., Nakayama, M., Takizawa, M., Kurakado, S., & Sugita, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344259 · Cited by 1
Pimenta, G. R., Gualque, M. W. D. L., Siqueto, M. J., Silva, S. D. M., Regasini, L. O., Mendes‐Giannini, M. J. S., & Fusco‐Almeida, A. M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00203-26
Ayala, M., Jakamartana, A., Costa, R. M. D. S., Cheung, E. C.-K., Bednarek, J. M., Moreau, C. T., & Brown, J. C. S. (2026) · mSphere · doi:10.1128/msphere.00432-26
Wang, Y., Wang, B., Li, J., Ma, S., Liu, P., Teng, Z., Zou, H., Cong, R., Sui, X., Li, X., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1856948
Rodrigues, M. M. (2012) · Cited by 1
Metadata
- Authors
- Uppuluri, P., Nett, J., Heitman, J., & Andes, D.
- Affiliations
- Duke Medical Center (US)
- University of Wisconsin–Madison (US)
- Corresponding author
- Heitman, Joseph
- Andes, David
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-03
- Volume
- 52
- Issue
- 3
- Pages
- 1127-1132
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2258509
- OpenAlex
- W2127992552
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 5 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 17 · 2012: 18
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NIH-R01)
- Department of Biology, Duke University
- National Heart, Lung, and Blood Institute (T32HL007899)
- National Institute of Allergy and Infectious Diseases (R01AI042159, R01AI42159, R01 AI50438, R01AI050438)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- Candida albicans, biofilm, calcineurin, calcineurin inhibitors, FK506, cyclosporine, fluconazole, drug synergy, antifungal resistance, azole antifungals, ergosterol biosynthesis, membrane perturbation, FKBP12, catheter-related infection, combination therapy
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Drug Synergism, Humans, Microbial Sensitivity Tests, Fluconazole, Tacrolimus, Cyclosporine, Biofilms, Drug Resistance, Fungal, Rats, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.